🇺🇸 FDA
Patent

US 11890354

Activatable antibodies that bind epidermal growth factor receptor and methods thereof

granted A61KA61K2039/505A61K39/3955

Quick answer

US patent 11890354 (Activatable antibodies that bind epidermal growth factor receptor and methods thereof) held by CytomX Therapeutics, Inc. expires Mon Feb 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
CytomX Therapeutics, Inc.
Grant date
Tue Feb 06 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
16
CPC classes
A61K, A61K2039/505, A61K39/3955, A61K47/68031, A61K47/6849